Best-Value Medicine (Teriparatide): Tetridar®

Information for Healthcare Professionals

The MMP recommends Tetridar® as a Best-Value Medicine (BVM) for teriparatide.

Prescribing Tetridar® will lead to significant savings for the health service.

The following presentation of Tetridar®, available on the High Tech Arrangement, is recommended as a best-value medicine (BVM):

- Tetridar® 20 micrograms (mcg)/80 microlitres solution for injection in pre-filled pen (PFP)

Tetridar® pre-filled pen

- Each pack contains one disposable PFP.
- Each dose that the PFP delivers contains 20 mcg of teriparatide in 80 microlitres.
- Each PFP contains 28 doses of 20 mcg of teriparatide.
- There is no latex present in the PFP; Tetridar® PFP is therefore suitable for patients with a latex allergy.
- It is supplied as a colourless, clear solution.

Storage

- Tetridar® PFP should be stored in a refrigerator (2°C - 8°C). It should not be frozen. It should not be used if it is, or has been, frozen.
- Once opened, a Tetridar® PFP may be stored for a maximum of 28 days at 2°C - 8°C (i.e. in a refrigerator).
- After administration of a dose of teriparatide from the Tetridar® PFP, it should be returned to the refrigerator.
- The Tetridar® PFP should be disposed of after 28 days from the date of first administration, even it if is not completely empty.

Dose Administration

- Each Tetridar® PFP pack contains a user manual that fully describes how to administer a dose from the PFP.
- Each Tetridar® PFP should be used by one patient only.
- Tetridar® PFP should not be used if the solution is cloudy, coloured or contains particles.
- Tetridar® PFP does not require priming prior to administration of the first dose from the PFP.
- A new, sterile needle must be used when administering each dose of teriparatide from the Tetridar® PFP.
- Needles are not supplied with the Tetridar® PFP and therefore they should be prescribed and dispensed separately.
- Tetridar® PFP can be used with Becton, Dickinson and Company pen needles of a gauge between 29 G and 31 G (diameter 0.25 – 0.33 mm) and a length of 5, 8 or 12.7 mm. These should be prescribed in conjunction with the Tetridar® PFP.
- Tetridar® PFP should be recapped when not in use to protect it from physical damage and light.
- The needle should be removed and placed in a sharps bin after administration of each dose of teriparatide. Tetridar® PFP should not be stored with a needle attached.
- The patient should record the date of administration of the first injection from a Tetridar® PFP. The PFP should be disposed of after 28 days from the date of first administration, even it if is not completely empty.
- When administration of a dose of teriparatide from the Tetridar® PFP is complete, the yellow shaft attached to the black injection button at the top of the PFP will no longer be visible.
- A demonstration video on how to administer a dose of teriparatide from the Tetridar® PFP is available at: https://www.teva.ie/our-products/article-pages/tetridar-teriparatide/

Similarities between Tetridar® PFP and the reference biological medicine (Forsteo® PFP)

- Tetridar® PFP has a shelf life of 24 months and Forsteo® PFP has a shelf life of two years.
- After administration of the first injection from the PFP, both Tetridar® PFP and Forsteo® PFP should be stored for a maximum of 28 days at 2°C - 8°C, after which time they should be disposed of, even if they are not completely empty.
- Both Tetridar® PFP and Forsteo® PFP do not require priming prior to administration of the first dose from the PFPs.
- A new, sterile needle must be used when administering each dose of teriparatide from both Tetridar® PFP and Forsteo® PFP.
- Needles are not supplied with the Tetridar ® PFP or Forsteo® PFP.
- Both Tetridar® PFP and Forsteo® PFP are disposable PFPs; the PFP and its contents are discarded 28 days after administration of the first injection from the PFP. A new PFP is then supplied to the patient.

- Tetridar® PFP and Forsteo® PFP have similar indicators to show that administration of a dose of teriparatide is complete. For both, the black injection button should be all the way in, and the yellow shaft should not be visible.



Teva Pharmaceuticals Ireland Patient Support Services

Teva Pharmaceuticals Ireland provide a patient support service to patients who have been prescribed Tetridar®. Point of Care Health Services provides this on behalf of Teva Pharmaceuticals Ireland.

The following services are available as part of the patient support service:

- Provision of nurse injection training and educational call in the patient's home or via remote video call, including a second visit when required
- Provision of follow-up support phone calls
- Sharps management service – this includes supply of sharps bins but not collection and disposal
- Access to educational materials, including an online instruction video on how to administer Tetridar®.

In order to avail of the patient support services for patients who have been prescribed Tetridar®, please contact Point of Care Health Services at (01) 499 2674 or email admin@pointofcare.ie.

Online referral & tracking: www.healthpoint.ie/teva

In order to obtain patient support materials for use in clinics, please contact: Collin Botha

- Email: collin.botha@teva.ie
- Phone: (087) 6685876

References:

1. Tetridar® 20 micrograms/80 microlitres solution for injection in pre-filled pen. Summary of Product Characteristics. Last revised 04/08/2022. Accessed at www.hpra.ie on 05/04/2024.

Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie. Adverse events should also be reported to Teva UK Limited on +44 (0) 207 540 7117 or medinfo@tevauk.com.